Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets

Am J Ther. 2016 Jan-Feb;23(1):e198-207. doi: 10.1097/MJT.0000000000000053.

Abstract

Arginine-glycine-aspartate (RGD)-binding integrins, including αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, αIIbβ3, and α8β1, recognize the tripeptide motif RGD in their ligands. RGD-binding integrins are involved in various cell functions, including cell proliferation, survival, differentiation, and motility that are critically important to both health and disease. The diagnostic and therapeutic value of some RGD-binding integrin inhibitors are either clinically proven or at different stages of development. In this review, we first summarized the structure and signaling characteristics of RGD-binding integrins. We then discussed the functions of RGD-binding integrins and their association with human disease. Finally, we recapitulated the research efforts and clinical trials of targeting RGD-binding integrins for the diagnosis and treatment of human disease. This comprehensive review of the current advances in RGD-binding integrins could assist scientists and clinicians in gaining a complete understanding of this group of molecules. It can also contribute to the design of new projects to further advance this field of research and to better apply the research results to benefit patients in clinical practice.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / drug therapy
  • Diagnostic Imaging
  • Humans
  • Integrins / antagonists & inhibitors*
  • Integrins / chemistry
  • Integrins / physiology
  • Neoplasms / drug therapy
  • Oligopeptides / metabolism*
  • Signal Transduction

Substances

  • Integrins
  • Oligopeptides
  • arginyl-glycyl-aspartic acid